Menu
Search
|

Menu

Close
X

Clementia Pharmaceuticals Inc CMTA.OQ (NASDAQ Stock Exchange Global Select Market)

10.90 USD
-- (--)
As of Jul 20
chart
Previous Close 10.90
Open --
Volume --
3m Avg Volume 16,765
Today’s High --
Today’s Low --
52 Week High 20.12
52 Week Low 9.00
Shares Outstanding (mil) 31.72
Market Capitalization (mil) 339.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.417
FY17
-4.303
FY16
-0.308
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
2.68
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-102.03
13.18
Return on Equity (TTM)
vs sector
--
15.09

EXECUTIVE LEADERSHIP

David Bonita
Chairman of the Board, Since
Salary: --
Bonus: --
Clarissa Desjardins
Chief Executive Officer, Founder, Director, Since
Salary: --
Bonus: --
Michael Singer
Chief Financial Officer, Since
Salary: --
Bonus: --
Eric Grinstead
Chief Commercial Officer, Since
Salary: --
Bonus: --
Donna Grogan
Chief Medical Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

550-4150 Sainte-Catherine West
MONTREAL   QC   H3Z 2Y5

Phone: +1514.9403610

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage.

SPONSORED STORIES